文献速递冠心病血脂与心血管预防

依洛尤单抗在已确诊动脉粥样硬化性心血管疾病患者中的长期应用

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
PubMed 文献 · Circulation · 2022-08-29

FOURIER开放标签扩展研究纳入6635例已确诊动脉粥样硬化性心血管疾病且基线LDL-C≥70 mg/dL的患者,中位随访5.0年,最长暴露8.4年。长期依洛尤单抗治疗不良事件发生率未超过母研究安慰剂组,且与延迟治疗相比进一步降低心血管事件风险。

要点

  • 长期依洛尤单抗治疗超过8年,安全性与母研究安慰剂组相当。
  • 开放标签扩展12周时中位LDL-C为30 mg/dL,63.2%患者LDL-C<40 mg/dL。
  • 早期依洛尤单抗治疗较延迟治疗降低MACE风险,包括心血管死亡风险降低23%。

核心结论

  • 长期依洛尤单抗降低LDL-C超过8年,不良事件发生率持续较低且未超过母研究安慰剂组,并较延迟治疗进一步减少心血管事件。

研究设计与样本

  • 完成FOURIER且所在中心参与的患者进入美国与欧洲的两项开放标签扩展研究(FOURIER-OLE),主要分析汇总两项研究。
  • FOURIER-OLE共纳入6635例患者,其中母研究随机至依洛尤单抗3355例、安慰剂3280例。

主要发现

  • FOURIER-OLE中位随访5.0年,母研究加扩展研究最长依洛尤单抗暴露8.4年。
  • FOURIER-OLE第12周时中位LDL-C为30 mg/dL,63.2%患者LDL-C<40 mg/dL。
  • 长期依洛尤单抗的严重不良事件、肌肉相关事件、新发糖尿病、出血性卒中及神经认知事件发生率未超过母研究安慰剂组且未随时间增加。
  • FOURIER-OLE随访期间,母研究随机至依洛尤单抗者较安慰剂者心血管死亡、心肌梗死、卒中或不定型心绞痛/冠状动脉血运重建住院风险降低15%(HR 0.85 [95%CI 0.75-0.96];P=0.008)。
  • 母研究随机至依洛尤单抗者心血管死亡、心肌梗死或卒中风险降低20%(HR 0.80 [95%CI 0.68-0.93];P=0.003),心血管死亡风险降低23%(HR 0.77 [95%CI 0.60-0.99];P=0.04)。

临床怎么用

  • 对已确诊动脉粥样硬化性心血管疾病且他汀治疗后LDL-C≥70 mg/dL的患者,长期使用依洛尤单抗安全且可持续降低LDL-C。
  • 尽早启动依洛尤单抗较延迟治疗可进一步降低心血管事件风险,支持在高危患者中早期强化降脂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was safe and well tolerated over a median of 2.2 years of follow-up. However, large-scale, long-term data are lacking. METHODS: The parent FOURIER trial randomized 27 564 patients with atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on statin to evolocumab versus placebo. Patients completing FOURIER at participating sites were eligible to receive evolocumab in 2 open-label extension studies (FOURIER-OLE [FOURIER Open-Label Extension]) in the United States and Europe; primary analyses were pooled across studies. The primary end point was the incidence of adverse events. Lipid values and major adverse cardiovascular events were prospectively collected. RESULTS: A total of 6635 patients were enrolled in FOURIER-OLE (3355 randomized to evolocumab and 3280 to placebo in the parent study). Median follow-up in FOURIER-OLE was 5.0 years; maximum exposure to evolocumab in parent plus FOURIER-OLE was 8.4 years. At 12 weeks in FOURIER-OLE, median LDL-C was 30 mg/dL, and 63.2% of patients achieved LDL-C <40 mg/dL on evolocumab. Incidences of serious adverse events, muscle-related events, new-onset diabetes, hemorrhagic stroke, and neurocognitive events with evolocumab long term did not exceed those for placebo-treated patients during the parent study and did not increase over time. During the FOURIER-OLE follow-up period, patients originally randomized in the parent trial to evolocumab versus placebo had a 15% lower risk of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization (hazard ratio, 0.85 [95% CI, 0.75-0.96]; P=0.008); a 20% lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80 [95% CI, 0.68-0.93]; P=0.003); and a 23% lower risk of cardiovascular death (hazard ratio, 0.77 [95% CI, 0.60-0.99]; P=0.04). CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifiers: NCT02867813 and NCT03080935.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022. PMID: 36031810. doi:10.1161/CIRCULATIONAHA.122.061620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。